BRAF and ameloblastoma: These studies confirm that BRAF V600E immunopositivity is correlated with BRAF V600E mutation status in ameloblastomas and can be considered a good method used as an initial screening test in identifying this mutation in ameloblastomas due to its simplicity, reliability, cost-effectiveness, and widespread adoption as the standard histopathological diagnostic procedure.